ONKOGEL and NanoONKO
We have developed “ONKOGEL”, a liposomal gel containing hydrophobic hydroxy-aluminum phthalocyanine, later “NanoONKO” nanoparticle drug formulation for the infrared photodynamic therapy of tumors based on a liposome nanoparticle mixture containing hydrophobic hydroxy-aluminum phthalocyanine.
TECHNOLOGY (INVENTION) DESCRIPTION:
ONKOGEL - Using a patented procedure of microfluidization, a micronized powder of water-insoluble hydroxy-aluminum phthalocyanine microcrystals is mixed with amorphous pharmaceutical grade lecithin in a desired buffer solution. Resulting liposomal suspension is than mixed with a translucent gel. NanoONKO - Using a patented procedure of microfluidization for NaYF4-Yb-Er upconversion nanoparticles mixed with a micronized powder of water-insoluble hydroxy-aluminum phthalocyanine microcrystals and with amorphous pharmaceutical grade lecithin in a desired buffer solution.
ADVANTAGES OVER EXISTING SOLUTIONS:
ONKOGEL: Short drug-to-light interval 670 nm irradiation penetrating more than 2 cm into the skin or tissue Expected short clearance Expected high efficiency Next generation is ready, i.e., patented nanoparticle drug formulation for curing by 980 nm light NanoONKO: Short drug-to-light interval 980 nm irradiation penetrating 4 cm into the skin or tissue Expected high efficiency Being one of the first application for nanomedicine Potential modification to 800 nm upconversion nanoparticles with the ability to excite commercially available photosenzitizers such as Foscan® (Temoporfin, manufactured by Biolitec, excitation of 652 nm)
DEVELOPMENT STATUS (STAGE):
O+N - Phase 3 (TRL 5 in preclinics; TRL 6, i.e., manufacturing in semi-industrial scale)
Nekvasil, M., Zadinová, M., Tahotná, L., Žáčková, M., Poučková, P., Ježek, P. An optimum modality for photodynamic therapy of tumors: gels containing liposomes with hydrophobic photosenzitizers. Drug. Dev. Res. 68, 235-252, 2007 Kostiv U, Kotelnikov I, Proks V, Šlouf M, Kučka J, Engstová H, Ježek P, Horák D. RGDS- and TAT-Conjugated Upconversion NaYF4:Yb3+/Er3+&SiO2 Nanoparticles: In vitro Human Epithelioid Cervix Carcinoma Cellular Uptake, Imaging and Targeting. ACS Appl Mater Interfaces. 8 (31), 20422-20431, 2016 ...
IP PROTECTION STATUS:
ONKOGEL - EP (EP 07817403.4), CAN, NOR and CZ patent NanoOnko - CZ patent, PCT/IB2018/057981
TECHNOLOGY / IP OWNERS :
ONKOGEL - 67% Institute of Physiology of the Czech Academy of Sciences, Prague; 33% RCD Limited, Dobřichovice NanoONKO - 75% Institute of Physiology of the Czech Academy of Sciences, Prague; 25% RCD Limited, Dobřichovice
More information is available upon signing a CDA / NDA (Confidential Disclosure Agreement / Non-Disclosure Agreement)